National Football League Players Ass'n v. National Football League

654 F. Supp. 2d 960, 2009 U.S. Dist. LEXIS 43576, 2009 WL 1457007
CourtDistrict Court, D. Minnesota
DecidedMay 22, 2009
DocketCivil 08-6254 (PAM/JJG), 08-6255 (PAM/JJG)
StatusPublished
Cited by1 cases

This text of 654 F. Supp. 2d 960 (National Football League Players Ass'n v. National Football League) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
National Football League Players Ass'n v. National Football League, 654 F. Supp. 2d 960, 2009 U.S. Dist. LEXIS 43576, 2009 WL 1457007 (mnd 2009).

Opinion

MEMORANDUM AND ORDER

PAUL A. MAGNUSON, District Judge.

This matter is before the Court on cross-Motions for Summary Judgment filed by all parties in these related cases.

BACKGROUND

In July and August 2008, players in the National Football League (“NFL”) submitted to random testing for steroids and other substances in accordance with the NFL’s Policy on Anabolic Steroids and Related Substances (the “Policy”). (Greenspan Decl. Ex. 1 (hereinafter “Policy”) at 4 (“Each week during the preseason and regular season, ten (10) players on every team will be tested.”).) The Policy’s testing regimen is administered by Defendant Dr. John Lombardo, who is denominated the “Independent Administrator” of the Policy. (Id. at Appx. B.) As the Independent Administrator, Lombardo has “the sole discretion to make determinations regarding the method by which players will be subjected to testing each week; selecting which players will be tested each week; deciding when tests will be administered; ... analyzing test results; ... and certifying violations for disciplinary or administrative action.” (Id. ¶ 2.) He is also responsible for “consulting] with players and Club physicians, overseeing] the development of educational materials, [and] participating] in research on steroids.... ” (Id.)

In late September and early October 2008, five players — Kevin Williams and Pat Williams of the Minnesota Vikings and Charles Grant, Deuce McAllister, and Will Smith of the New Orleans Saints — were informed that their samples had tested positive for bumetanide, a prescription diuretic that is banned under the Policy because it may mask the presence of steroids. 1 The Policy provides that “[t]he first time a player violates this Policy by testing positive [for a banned substance] ... he will be suspended without pay for a minimum of four regular and/or postseason games.” (Id. ¶ 6 (emphasis in original).) Thus, the NFL suspended the players for four games.

The players appealed their suspensions. Under the terms of the Policy, appeals are presented at a hearing before the Commissioner or his designee at which the player may be represented by counsel and may present evidence. (Id. ¶ 10.) The Policy further provides that the Hearing Officer’s written decision “will constitute a full, final, and complete disposition of the appeal” and “will be binding on all parties.” (Id.) The Commissioner designated Defendant Jeffrey Pash, the NFL’s chief legal officer, to be the Hearing Officer in the appeals. 2

At the hearing, the players presented evidence that they took an over-the-counter dietary supplement called “StarCaps,” which ostensibly provides weight-loss benefits. Although bumetanide is not listed as an ingredient in StarCaps, the evidence established that the StarCaps the players took contained bumetanide. Thus, the players all unknowingly ingested bumetanide.

*964 Under normal circumstances, the unknowing ingestion of a banned substance will not excuse a violation of the Policy. The Policy warns repeatedly that players are responsible for what is in their bodies, and states that “a positive test result will not be excused because a player was unaware that he was taking a [banned substance].” (Id. ¶ 3.E.) The players argued, however, that theirs was not a normal circumstance. The evidence established that Lombardo and the NFL knew in 2006 that at least some StarCaps capsules contained bumetanide. Indeed, after several players tested positive for bumetanide after taking StarCaps in 2006, Lombardo and the NFL asked an independent laboratory to analyze StarCaps for the presence of bumetanide. 3 The laboratory found bumetanide in StarCaps and informed Birch and Lombardo of the results. The laboratory also published the results of the tests in the November/December 2007 Journal of Analytical Toxicology. After this testing, Defendant Adolpho Birch, the NFL’s Vice President of Law and Labor Policy, informed the National Football League Players Association (“NFLPA” or “Union”) that players were prohibited from providing endorsements for Balanced Health Products, the distributor of StarCaps. (Saints players Arbitration R. Ex. 53.) Birch also sent a memorandum to each team’s president, general manager, and head athletic trainer that players were not to endorse Balanced Health Products. (Id. Ex. 52.) Neither Lombardo nor Birch, however, told the teams, trainers, agents, or players that StarCaps contained bumetanide or any banned substance. Moreover, despite the lab director’s request that the NFL report the information about StarCaps to the Food & Drug Administration (“FDA”), Birch declined to do so. (Vikings players Appeal Hr’g T. at 238 (Lombardo Test.).)

In decisions dated December 2, 2008, Mr. Pash upheld the suspensions of all five players. (Saints players Arbitration R. Ex. 1; Vikings players Arbitration R. Ex. 1.) He discussed the Policy’s position on dietary supplements, noting that players received repeated warnings that over-the-counter supplements might contain ingredients not listed on the label and that a positive test would not be excused because the supplement’s ingredient list did not disclose the presence of a banned substance. (See, e.g., Vikings players Arbitration R. Ex. 1 at ¶¶ 7-9 (discussing numerous memoranda to players regarding supplements).) Mr. Pash then turned to the language of the Policy as applied to the facts at hand:

There is no question that the policy embodies a collectively-bargained rule of strict liability — a rule that players alone are responsible for what is in their bodies; that inadvertent or unknowing use of a prohibited substance will not excuse a positive test; and that supplements are used at the player’s own risk. Similarly, there is no question that at the time that he used StarCaps as well as at the time of the hearing, each player clearly understood that rule and what it means.

(Id. at 6.)

None of the players contested their positive test results. They instead argued that those positive results should be excused “because the NFL and Dr. Lombardo were aware that StarCaps contained an undisclosed banned substance, bumetanide, but did not specifically advise NFL players of this fact.” (Id.) As Mr. Pash put it in his decisions on the appeals, “even *965 though [none of the] player[s] contacted Dr. Lombardo about StarCaps (as the Policy directs them to do), they contend that where specific evidence is available about a particular product, a specific warning is required, and the failure to extend such a warning should excuse any violation of the Policy associated with that product.” (Id.) Mr. Pash found that the players’ position “flies in the face of nearly two decades of history” because the Policy has always adhered to the “fundamental principle” of strict liability that “puts the burden on players to be responsible and accountable for what is in their bodies.” (Id. at 7) Mr. Pash thus concluded that the language of the Policy required that the suspensions be upheld.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. National Football League
794 N.W.2d 391 (Court of Appeals of Minnesota, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
654 F. Supp. 2d 960, 2009 U.S. Dist. LEXIS 43576, 2009 WL 1457007, Counsel Stack Legal Research, https://law.counselstack.com/opinion/national-football-league-players-assn-v-national-football-league-mnd-2009.